BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 31 May 2018
At a glance
- Drugs Dasatinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 14 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.